Advanced Viral Research Corp. Announces Agreement With Selikoff Center To Conduct Clinical Research Studies in Israel Using Product R

Apr 03, 2001, 01:00 ET from Advanced Viral Research Corp.

    YONKERS, N.Y., April 3 /PRNewswire/ -- Advanced Viral Research Corp.
 (OTC Bulletin Board:   ADVR) today announced an agreement with the Selikoff
 Center for Environmental Health and Human Development in Ra'anana, Israel to
 develop research and clinical trials using Product R.  Beginning with clinical
 trials using Product R to mitigate the toxic effects of chemotherapy in
 patients with advanced stage cancer, the scientists at the Selikoff Center
 will develop further clinical trials using Product R to treat other diseases
 as well.  ADVR's objective is for the Selikoff Center to begin formal
 controlled clinical trials in Israel later this year.  It is anticipated that
 the trials developed by The Selikoff Center will support the U.S. FDA
 applications currently under the aegis of GloboMax LLC.
     The Selikoff Center in Ra'anana, Israel, under the leadership of Dr. Alf
 Fischbein, is recognized for its studies of environmental health problems in
 various parts of the world.  Research scientists, including Drs. Jose Iscovich
 and Laurence Freedman and their consultants have been at the forefront in
 conducting population based medical studies and acquiring multiple levels of
 clinical data.
     Dr. Alf Fischbein has been Professor of Environmental Medicine at The
 Mount Sinai School of Medicine and was, for many years, a close associate of
 the late Dr. Irving Selikoff, one of the world's leaders in environmental
 health.
     Dr. Jose Iscovich is an internationally recognized cancer epidemiologist.
 He is a frequent visiting scientist at the International Agency for Research
 on Cancer (IARC) in Lyon, France and has authored many landmark IARC
 monographs.  Dr. Iscovich is past Director of the Israel Cancer Registry and
 has expertise in study design, quality control and quality assurance.
     Dr. Laurence Freedman was acting Chief of the Biometric Branch at The
 National Cancer Institute of The National Institutes of Health in Bethesda,
 Maryland.  His work involves developing statistically valid clinical trials,
 including the celebrated clinical trial of tamoxifen for therapy of breast
 cancer.
     Shalom Z. Hirschman, M.D., President and CEO of Advanced Viral Research
 Corp. stated, "It is a particular pleasure and privilege for me to work with
 the scientists at The Selikoff Center who will be conducting rigorous clinical
 trials of Product R in Israel.  Our goal is to place Product R into the hands
 of the patients, many of whom are in desperate need of this new kind of
 immunomodulator therapy, as quickly and efficiently as possible."
     "We are excited to be developing clinical research trials of Product R in
 Israel in collaboration with ADVR.  We look forward to participating in
 'cutting edge' scientific research with this innovative broad-spectrum
 immunonomodulator and adding to the knowledge of the wide clinical potential
 of Product R," commented Dr. Alf Fischbein.
     Scientists at the Weizmann Institute of Science in Rehovot, Israel are
 currently conducting basic research on the effects of Product R on the human
 immune system, including T-cell function.
 
     ABOUT PRODUCT R
     Product R peptide nucleic acid-type immunomodulator that, in both
 laboratory and clinical studies, has been shown to stimulate the
 pro-inflammatory responses required to combat viral infections such as AIDS
 and human papilloma virus and to dampen aberrant autoimmune-type inflammatory
 responses, such as occur in patients with rheumatoid arthritis.  Therefore,
 Product R has been termed a "switch-type" immunomodulator.  Product R has also
 shown promise in its ability to mitigate the toxic side-effects of other
 drugs, including those to treat HIV infection and chemotherapeutic drugs used
 in the treatment of cancers.
 
     ABOUT ADVANCED VIRAL RESEARCH CORP.
     Advanced Viral Research Corp., based in Yonkers, New York, is a
 biopharmaceutical firm committed to researching, developing and bringing to
 market new, effective therapies for viral and other diseases.  Its flagship
 drug, Product R, is a non-toxic peptide nucleic acid-type immunomodulator,
 which has direct anti-viral effects against select viruses such as adenovirus
 and human papilloma virus, and has been shown to have beneficial therapeutic
 effects against viral diseases such as AIDS and autoimmune diseases like
 rheumatoid arthritis.
 
     Note: This news release contains forward-looking statements that involve
 risks associated with clinical development, regulatory approvals, including
 application to the FDA, product commercialization and other risks described
 from time to time in the SEC reports filed by ADVR.  Product R has not been
 approved by the U.S. Food and Drug Administration or any comparable agencies
 of any other countries.
 
 

SOURCE Advanced Viral Research Corp.
    YONKERS, N.Y., April 3 /PRNewswire/ -- Advanced Viral Research Corp.
 (OTC Bulletin Board:   ADVR) today announced an agreement with the Selikoff
 Center for Environmental Health and Human Development in Ra'anana, Israel to
 develop research and clinical trials using Product R.  Beginning with clinical
 trials using Product R to mitigate the toxic effects of chemotherapy in
 patients with advanced stage cancer, the scientists at the Selikoff Center
 will develop further clinical trials using Product R to treat other diseases
 as well.  ADVR's objective is for the Selikoff Center to begin formal
 controlled clinical trials in Israel later this year.  It is anticipated that
 the trials developed by The Selikoff Center will support the U.S. FDA
 applications currently under the aegis of GloboMax LLC.
     The Selikoff Center in Ra'anana, Israel, under the leadership of Dr. Alf
 Fischbein, is recognized for its studies of environmental health problems in
 various parts of the world.  Research scientists, including Drs. Jose Iscovich
 and Laurence Freedman and their consultants have been at the forefront in
 conducting population based medical studies and acquiring multiple levels of
 clinical data.
     Dr. Alf Fischbein has been Professor of Environmental Medicine at The
 Mount Sinai School of Medicine and was, for many years, a close associate of
 the late Dr. Irving Selikoff, one of the world's leaders in environmental
 health.
     Dr. Jose Iscovich is an internationally recognized cancer epidemiologist.
 He is a frequent visiting scientist at the International Agency for Research
 on Cancer (IARC) in Lyon, France and has authored many landmark IARC
 monographs.  Dr. Iscovich is past Director of the Israel Cancer Registry and
 has expertise in study design, quality control and quality assurance.
     Dr. Laurence Freedman was acting Chief of the Biometric Branch at The
 National Cancer Institute of The National Institutes of Health in Bethesda,
 Maryland.  His work involves developing statistically valid clinical trials,
 including the celebrated clinical trial of tamoxifen for therapy of breast
 cancer.
     Shalom Z. Hirschman, M.D., President and CEO of Advanced Viral Research
 Corp. stated, "It is a particular pleasure and privilege for me to work with
 the scientists at The Selikoff Center who will be conducting rigorous clinical
 trials of Product R in Israel.  Our goal is to place Product R into the hands
 of the patients, many of whom are in desperate need of this new kind of
 immunomodulator therapy, as quickly and efficiently as possible."
     "We are excited to be developing clinical research trials of Product R in
 Israel in collaboration with ADVR.  We look forward to participating in
 'cutting edge' scientific research with this innovative broad-spectrum
 immunonomodulator and adding to the knowledge of the wide clinical potential
 of Product R," commented Dr. Alf Fischbein.
     Scientists at the Weizmann Institute of Science in Rehovot, Israel are
 currently conducting basic research on the effects of Product R on the human
 immune system, including T-cell function.
 
     ABOUT PRODUCT R
     Product R peptide nucleic acid-type immunomodulator that, in both
 laboratory and clinical studies, has been shown to stimulate the
 pro-inflammatory responses required to combat viral infections such as AIDS
 and human papilloma virus and to dampen aberrant autoimmune-type inflammatory
 responses, such as occur in patients with rheumatoid arthritis.  Therefore,
 Product R has been termed a "switch-type" immunomodulator.  Product R has also
 shown promise in its ability to mitigate the toxic side-effects of other
 drugs, including those to treat HIV infection and chemotherapeutic drugs used
 in the treatment of cancers.
 
     ABOUT ADVANCED VIRAL RESEARCH CORP.
     Advanced Viral Research Corp., based in Yonkers, New York, is a
 biopharmaceutical firm committed to researching, developing and bringing to
 market new, effective therapies for viral and other diseases.  Its flagship
 drug, Product R, is a non-toxic peptide nucleic acid-type immunomodulator,
 which has direct anti-viral effects against select viruses such as adenovirus
 and human papilloma virus, and has been shown to have beneficial therapeutic
 effects against viral diseases such as AIDS and autoimmune diseases like
 rheumatoid arthritis.
 
     Note: This news release contains forward-looking statements that involve
 risks associated with clinical development, regulatory approvals, including
 application to the FDA, product commercialization and other risks described
 from time to time in the SEC reports filed by ADVR.  Product R has not been
 approved by the U.S. Food and Drug Administration or any comparable agencies
 of any other countries.
 
 SOURCE  Advanced Viral Research Corp.